Adaptimmune Therapeutics plc

  • Home
  • Our Company
    • Overview arrow_forward
    • Partners arrow_forward
    • Board of Directors arrow_forward
    • Leadership Team arrow_forward
    • Scientific Advisory Board arrow_forward
    • Perspectives arrow_forward
    • COVID-19 arrow_forward
  • Pipeline
    • Overview arrow_forward
    • ADP-A2M4 arrow_forward
    • ADP-A2M4CD8 arrow_forward
    • ADP-A2AFP arrow_forward
    • ADP-A2M10 arrow_forward
  • Technology
    • Overview arrow_forward
    • Manufacturing arrow_forward
    • Publications arrow_forward
  • Patients & Families
    • Overview arrow_forward
    • Taking Part in Our Clincial Trials arrow_forward
    • Cancer Info arrow_forward
    • Cancer Immunotherapy Month arrow_forward
    • Videos arrow_forward
    • Engagement with Patient Organizations arrow_forward
  • Clinical Trials
  • Investors & Media
    • Overview arrow_forward
    • News & Events arrow_forward
    • Annual Shareholder Meeting arrow_forward
    • Company Info arrow_forward
    • Financial Info arrow_forward
    • Stock Data arrow_forward
    • SEC Filings arrow_forward
    • Governance arrow_forward
    • Media arrow_forward
  • Contact
  • Careers
    • Overview arrow_forward
    • U.S. Careers arrow_forward
    • UK Careers arrow_forward

Press Releases

Investors & Media

Investors & Media

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Annual Shareholder Meeting
  • Company Info
    • Overview
    • Leadership Team
    • Board of Directors
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Media
  • News & Media

  • Press Releases
  • Presentations
  • Events
Feb 20, 2020 4:00pm EST

Adaptimmune to Report Full Year / Q4 2019 Financial Results and Business Update on Thursday, February 27, 2020

Feb 18, 2020 8:00am EST

Adaptimmune Announces Appointment of Gavin Wood as Chief Financial Officer

Feb 07, 2020 4:05pm EST

Adaptimmune Therapeutics plc Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional American Depositary Shares

Jan 24, 2020 4:30pm EST

Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares

Jan 22, 2020 8:48am EST

Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares

Jan 21, 2020 4:08pm EST

Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares

Jan 14, 2020 2:07am EST

Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies

Jan 13, 2020 8:30am EST

Adaptimmune Appoints Elliot Norry as Chief Medical Officer and Makes Changes to R&D Leadership

Jan 13, 2020 2:00am EST

Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications

Dec 03, 2019 8:30am EST

Regenerative Medicine Advanced Therapy Designation Granted by FDA to ADP‑A2M4 for the Treatment of Synovial Sarcoma

RSS
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...19
  • Next
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
Adaptimmune Therapeutics plc
Privacy Policy Disclaimer Search Sitemap Terms of Use Supply Terms
Linedin Twitter Youtube
© 2021 Adaptimmune Therapeutics plc. All Rights Reserved.